Clinical-stage company OncoMed Pharmaceuticals has announced the issuance of US patent for methods of treating cancer with its antibody vantictumab (OMP-18R5) through 2029. Targeting and inhibiting the Wnt pathway, Vantictumab was ...
Tags: Vantictumab, OncoMed